First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia

Journal of Clinical Oncology

Volumn 22, Issue 9, 2004, Pages 1598-1604

  Brandes, Alba A ^a   Basso, Umberto ^a   Reni, Michele ^a   Vastola, Francesca ^a   Tosoni, Alicia ^a   Cavallo, Giovanna ^a   Scopece, Luciano ^a   Ferreri, Andres J ^a   Panucci, Maria G ^a   Monfardini, Silvio ^a   Ermani, Mario ^a  

^a BELLARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CISPLATIN PLUS TEMOZOLOMIDE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; GLIOBLASTOMA; GRANULOCYTOPENIA; HUMAN; MULTICENTER STUDY; NEUROTOXICITY; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; AGRANULOCYTOSIS; BRAIN TUMOR; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG INTERACTION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; TUMOR RECURRENCE;

ADULT; AGED; AGRANULOCYTOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CISPLATIN; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; GLIOBLASTOMA; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 2442717967     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.11.019     Document Type: Article

References (22)

1. Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578, 1999
2. Yung A, Albright R, Olson J, et al: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588-593, 2000
3. Brada M, Hoang-Xuan K, Rampling R, et al: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:259-266, 2001
4. Brandes AA, Pasetto LM, Vastola F, et al: Temozolomide in patients with high-grade gliomas. Oncology 59:181-186, 2000
5. -6-alkylguanine- DNA alkyltransferase (AGAT). A mechanism of resistance to alkylators, with protracted low-dose oral schedules of temozolomide. Br J Cancer 88:1004-1011, 2003
6. 6-alkylguanine DNA alkyltransferase. Clin Cancer Res 7:2309-2317, 2001
7. Huncharek M, Muscat J: Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Res 18:1303-1311, 1998
8. Yung WKA, Mechtler L, Gleason MJ, et al: Intravenous carboplatin for recurrent malignant glioma: A phase II study. J Clin Oncol 9:860-864, 1991
9. -6-alkylguanine-DNA Alkyltransferase in HeLa cells by cisplatin. Carcinogenesis 10:1681-1684, 1989
10. Piccioni D, D'Altri S, Papa G, et al: Cisplatin increases sensitivity of human leukemic blasts to triazene compounds. J Chemother 7:224-229, 1995
11. Britten CD, Rowinsky EK, Baker SD, et al: A phase I and pharmacokinetic study of Temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res 5:1629-1637, 1999
12. National Cancer Institute: Reporting Guidelines, Common Toxicity Criteria V2.0 (CTC). http://ctep.cancer.gov/reporting/CTC-3.html
13. Kaplan EL, Meier P: Non parametric estimation for incomplete observation. J Am Stat Assoc 53:457-481, 1958
14. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
15. Makuch RW, Simon RM: Sample size considerations for non-randomized comparative studies. J Chron Dis 33:175-181, 1980
16. Cox DR: Regression models and life tables. J R Stat Soc 34:187-202, 1972
17. Groves MD, Puduvalli VK, Hess KR, et al: Phase II trial of temozolomide plus matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20:1383-1388, 2002
18. Jaeckle KA, Hess KR, Yung WK, et al: Phase II evaluation of temozolomide and 13-cis retinoic acid for the treatment of recurrent and progressive malignant glioma: A North American Brain Tumor Consortium Study. J Clin Oncol 21:2305-2311, 2003
19. Brandes AA, Palmisano V, Pasetto LM, et al: High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults. Cancer Invest 19:41-48, 2001
20. 6-alkylguanine DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851-3857, 1998
21. 6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 16:3570-3576, 1998
22. Grant R, Liang BC, Slattery J, et al: Chemotherapy response criteria in malignant glioma. Neurology 48:1336-1340, 1997